NEW YORK – Natera said on Monday that it has sued ArcherDx, alleging infringement of a recently issued patent covering target amplification.
In its complaint, filed with the US District Court of Delaware, San Carlos, California-based Natera said that ArcherDx, based in Boulder, Colorado, infringes its US Patent No. 10,538,814 titled "Methods for Simultaneous Amplification of Target Loci." The patent, issued on Jan. 21, covers methods that use multiplex PCR to amplify several nucleic acid regions in the same reaction for sequencing.
Specifically, Natera alleges that certain cell-free DNA-based oncology products sold by Archer Dx infringe the '814 patent.
The company is seeking injunctive relief and monetary damages.
"Natera will enforce its intellectual property rights and will stop unlicensed use of its patented technology in the field of minimal residual disease and personalized cancer monitoring," Gary Frischling, a lawyer at Milbank LLP who represents Natera in the matter, said in a statement.
Earlier this month, Natera sued CareDx for infringing a different patent, US Patent No. 10,526,658, which covers cell-free DNA-based diagnostic methods and was awarded to Natera Jan. 7.